Omnicell Q2 Outlook: Total Revenues $250M - $260M Vs. $261.88M Estimate, Adj. EPS $0.10-$0.20 Vs. $0.27 Estimate

5/2/24 7:42:09 AM ET

Computer Manufacturing

Technology

Get the next $OMCL alert in real time by email

The table below summarizes Omnicell's second quarter and full year 2024 guidance outlined above.

	Q2 2024	2024
Bookings	Not provided	$750 million - $875 million
Total Revenues	$250 million - $260 million	$1.045 billion - $1.120 billion
Product Revenues	$140 million - $145 million	$605 million - $650 million
Service Revenues	$110 million - $115 million	$440 million - $470 million
Technical Services Revenues	Not provided	$220 million - $235 million
Advanced Services Revenues	Not provided	$220 million - $235 million
Non-GAAP EBITDA	$14 million - $20 million	$90 million - $120 million
Non-GAAP Earnings Per Share	$0.10 - $0.20	$0.90 - $1.40

Get the next $OMCL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OMCL

Date	Price Target	Rating	Analyst
10/31/2024	$44.00 → $57.00	Buy → Neutral	BofA Securities
8/2/2024	$26.00 → $39.00	Underweight → Equal Weight	Barclays
1/3/2024	$33.00	Underweight	Barclays
11/3/2023	$39.00 → $28.00	Underweight → Equal Weight	Wells Fargo
11/3/2023		Buy → Neutral	BTIG Research
11/3/2023	$70.00 → $39.00	Neutral → Overweight	Piper Sandler
10/11/2023		Overweight → Sector Weight	KeyBanc Capital Markets
9/26/2023	$56.00 → $39.00	Underweight	Wells Fargo

More analyst ratings

$OMCL
Press Releases

Fastest customizable press release news feed in the world

Omnicell Announces Pricing of $150 Million Convertible Senior Notes Offering
Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell") today announced the pricing of $150.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Omnicell also granted the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes. The sale of the notes is expected to close on November 22, 2024, subject to cu
11/20/24 2:00:00 AM ET
$OMCL
Computer Manufacturing
Technology
Omnicell Announces Proposed Private Placement of $150 Million of Convertible Senior Notes
Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell") today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Omnicell also intends to grant the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes. The notes will
11/18/24 4:12:00 PM ET
$OMCL
Computer Manufacturing
Technology
Omnicell Announces Third Quarter 2024 Results
Omnicell delivers solid third quarter financial results Total revenues of $282 million GAAP net income per diluted share of $0.19 Non-GAAP net income per diluted share of $0.56 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today announced results for its third quarter ended September 30, 2024. Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, "We are pleased to deliver another consecutive quarter of solid financial performance, with results within or exceeding each of ou
10/30/24 6:30:00 AM ET
$OMCL
Computer Manufacturing
Technology

Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer
The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024
9/25/24 4:01:00 PM ET
$OMCL
Computer Manufacturing
Technology
Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer
FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me
4/22/24 4:05:00 PM ET
$CLOV
$OMCL
Medical Specialities
Health Care
Computer Manufacturing
Technology
Omnicell Elects Eileen Voynick to Board of Directors
Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e
1/11/24 4:00:00 PM ET
$MDRX
$OMCL
$CDK
EDP Services
Technology
Computer Manufacturing
Retail: Computer Software & Peripheral Equipment

$OMCL
Financials

Live finance-specific insights

Omnicell Announces Third Quarter 2024 Results
Omnicell delivers solid third quarter financial results Total revenues of $282 million GAAP net income per diluted share of $0.19 Non-GAAP net income per diluted share of $0.56 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today announced results for its third quarter ended September 30, 2024. Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, "We are pleased to deliver another consecutive quarter of solid financial performance, with results within or exceeding each of ou
10/30/24 6:30:00 AM ET
$OMCL
Computer Manufacturing
Technology
Omnicell to Release Third Quarter 2024 Financial Results on October 30, 2024
Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the third quarter 2024, before market open on Wednesday, October 30, 2024. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 6944646. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About Omnice
10/7/24 5:35:00 PM ET
$OMCL
Computer Manufacturing
Technology
Omnicell Announces Second Quarter 2024 Results
Results exceed previously issued second quarter guidance across all metrics Total revenues of $277 million GAAP net income per diluted share of $0.08 Non-GAAP net income per diluted share of $0.51 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today announced results for its second quarter ended June 30, 2024. Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, "We are pleased with the second quarter results that we announced today, which exceeded our previously issue
8/1/24 6:30:00 AM ET
$OMCL
Computer Manufacturing
Technology

Omnicell Q2 Outlook: Total Revenues $250M - $260M Vs. $261.88M Estimate, Adj. EPS $0.10-$0.20 Vs. $0.27 Estimate

Chat with this insight

Recent Analyst Ratings for $OMCL

$OMCL Press Releases

Fastest customizable press release news feed in the world

Omnicell Announces Pricing of $150 Million Convertible Senior Notes Offering

Omnicell Announces Proposed Private Placement of $150 Million of Convertible Senior Notes

Omnicell Announces Third Quarter 2024 Results

$OMCL Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

$OMCL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$OMCL SEC Filings

$OMCL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$OMCL Leadership Updates

Live Leadership Updates

$OMCL Market Insights

Live Market Insights

EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 225 shares, decreasing direct ownership by 0.46% to 49,224 units (SEC Form 4)

CHAIRMAN, PRESIDENT AND CEO Lipps Randall A covered exercise/tax liability with 1,155 shares, decreasing direct ownership by 0.70% to 163,561 units (SEC Form 4)

EVP & CFO Etta Nchacha covered exercise/tax liability with 593 shares, decreasing direct ownership by 0.80% to 73,731 units (SEC Form 4)

Omnicell Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Omnicell Inc.

Omnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Omnicell downgraded by BofA Securities with a new price target

Omnicell upgraded by Barclays with a new price target

Barclays initiated coverage on Omnicell with a new price target

Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

Omnicell Elects Eileen Voynick to Board of Directors

Benchmark Reiterates Buy on Omnicell, Maintains $38 Price Target

Benchmark Reiterates Buy on Omnicell, Maintains $38 Price Target

Omnicell Reaffirms FY24 Outlook: Adj EPS $0.90-1.40 vs $1.07 Est; Sees Sales $1.045B-1.120B vs $1.06B Est

$OMCL Financials

Live finance-specific insights

Omnicell Announces Third Quarter 2024 Results

Omnicell to Release Third Quarter 2024 Financial Results on October 30, 2024

Omnicell Announces Second Quarter 2024 Results

Recent Analyst Ratings for
$OMCL

$OMCL
Press Releases

$OMCL
Large Ownership Changes

$OMCL
Insider Trading

$OMCL
SEC Filings

$OMCL
Analyst Ratings

$OMCL
Leadership Updates

$OMCL
Market Insights

$OMCL
Financials